Bisphosphonates and other bone agents for breast cancer

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  O'Carrigan, Brent ^a,b   Wong, Matthew H F ^c   Willson, Melina L ^b   Stockler, Martin R ^b   Pavlakis, Nick ^d   Goodwin, Annabel ^e,f,g  

^a Chris O'Brien Lifehouse   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GOSFORD HOSPITAL   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e University of Sydney   (Australia)

^f ANZAC Research Institute   (Australia)

^g SOUTH WESTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PLACEBO; BONE DENSITY CONSERVATION AGENT; CLODRONIC ACID; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DRUG EFFICACY; EARLY CANCER; FRACTURE; HUMAN; HYPERCALCEMIA; MENOPAUSE; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT PLANNING; BONE TUMOR; BREAST TUMOR; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SECONDARY;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DENOSUMAB; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85032579376     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003474.pub4     Document Type: Review

References (252)

1. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky P, Jakesz R, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Research 2011;71:S1-2. 6946360
2. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine 2009;360(7):679-91. 6946361
3. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology 2011;12(7):631-41. 6946362
4. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology 2015; Vol. 26, issue 2:313-20. 6946363
5. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Poestlberger S, Dubsky PC, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. Journal of Clinical Oncology 2010;28(15 Suppl):533. 6946364
6. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;386(9992):433-43. [NCT00556374]6946366
7. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer: results from 3, 425 post-menopausal patients of the ABCSG18 trial. Journal of Clinical Oncology 2015;33(15 Suppl):504. [0732-183X]6946367
8. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. The impact of adjuvant denosumab on disease-free survival: results from 3, 425 postmenopausal patients of the ABCSG-18 trial. Cancer Research 2016;76(4 Suppl):S2-02. [0008-5472]6946368
9. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology 2010;11(5):421-8. 3271746
10. Aft RL, Naughton M, Trinkaus K, Weilbaecher K. Effect of (neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. British Journal of Cancer 2012;107(1):7-11. 3271745
11. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Journal of Clinical Oncology 1998;16(6):2038-44. 6946370
12. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New England Journal of Medicine 1996;335(24):1785-91. 6946371
13. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000;88(5):1082-90. 6946372
14. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo-controlled trial. Journal of Clinical Oncology 1999;17(3):846-54. 6946373
15. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncology 2014;15(9):997-1006. 6946375
16. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment 2011;127(2):429-38. 6946376
17. Coleman R, Woodward E, Turner L, Marshall H, Collinson M, Dodwell D, et al. Impact of zoledronic acid on fractures, bone mineral density and bone remodeling in the AZURE trial (BIG 01-04). Cancer Research 2011;71(24 Suppl):P2-19-01. 6946377
18. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine 2011;365(15):1396-405. 6946378
19. Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, et al. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Research 2012;72(24 Suppl):S6-4. 6946379
20. Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Cancer Research 2010;70(24 Suppl):S4-5. 6946380
21. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. British Journal of Cancer 2010;102(7):1099-105. 6946381
22. Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). Journal of Clinical Oncology 2013;31(21):2685-91. 6946382
23. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology 2003;14(9):1399-405. 3271762
24. Body JJ, Lichinitser MR, Diehl I, Schlosser K, Pfarr E, Cavalli F, et al. Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. 3271763
25. Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer 2004;40(11):1704-12. 3271764
26. Lyubimova N, Kushlinksky NE, Lichinitser MR. Long-term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease. 15th Annual Multinational Association of Supportive Care in Cancer (MASCC) Meeting; 2003. New York: Supportive Care in Cancer, 2003. 3271765
27. Body JJ, Diel I, Bell R, Pecherstorfer M, Lichinitser M, Lazarev A, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111(3):306-12. 3271767
28. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. British Journal of Cancer 2004;90(6):1133-7. 3271768
29. Himelstein AL, Qin R, Novotny PJ, Seisler DK, Khatcheressian JL, Roberts JD, et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of Clinical Oncology 2015; Vol. 33, issue 15 Suppl:9501. [0732-183X]6946384
30. NCT00869206 . Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. clinicaltrials.gov/ct2/show/NCT00869206 Date first received: 24 March 2009. 6946385
31. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Cabresi F, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised, multicenter phase III trial. Annals of Oncology 1994;5(Suppl 7):41-4. 3271792
32. Conte PF, Latrielle J, Mauriac L, Calbresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. Journal of Clinical Oncology 1996;14(9):2552-9. 3271793
33. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallweiner D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine 1998;339(6):357-63. 3271795
34. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Annals of Oncology 2008;19(12):2007-201. 3271796
35. Jaschke A, Bastert G, Solomayer EF, Costa S, Scheutz F, Diel JJ. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow: a long-term follow-up. Journal of Clinical Oncology 2004;22(14 Suppl):529. 3271797
36. Diel IJ, Marschner N, Kindler M, Lange O, Untach M, Hurtz HJ, et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (abstract 488). Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999. 3271799
37. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento A-L, Selander K, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983;1(8317):146-9. 3271801
38. Elomaa I, Blomqvist C, Porkka, Holtstrom T, Taube T, Lamberg-Allardt C, et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy 1988;42(2):111-6. 3271802
39. Elomma I, Blomqvist L, Porkka L, Lamberg-Allardt C, Borgstrom GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987;8(Suppl 1):53-6. 3271803
40. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clinical Breast Cancer 2012;12(1):40-8. 6946387
41. Llombarto A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. ASCO Breast Cancer Symposium; 2009; Chicago. Chicago: American Society of Clinical Oncology, 2009. 6946388
42. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology 2009;27(10):1564-71. 3271805
43. Suarez T, Fizazi K, Rahim Y, Wilson J, Fan M, Jun S, et al. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology 2006;24(18 Suppl):8562. 3271806
44. Moebus VJ, Von Minckwitz G, Jackisch C, Lueck H-J, Schneeweiss A, Tesch H, et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer-final efficacy analysis. Journal of Clinical Oncology 2014;32(5 Suppl):1009. 6946391
45. Möbus V, Diel I J, Harbeck N, Elling D, Jackisch C, Thomssen C, et al. GAIN study: a phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis. Cancer Research 2011;71(24):S2-4. 6946390
46. NCT00196872 . A study to compare ETC vs EC-TX and ibandronate vs observation in patients with node-positive primary breast cancer. clinicaltrials.gov/ct2/show/NCT00196872 Date first received: 12 September 2005. 6946392
47. von Minckwitz G, Mobus V, Schneeweiss A, Huober J, Thomssen C, Untch M, et al. German Adjuvant Intergroup Node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. Journal of Clinical Oncology 2013;31(28):3531-9. 6946393
48. Heras P, Hatzopoulos A, Mitsibounas D. Efficacy of ibandronate for the prevention of skeletal-related events in breast cancer patients with metastatic bone disease. European Journal of Cancer 2005;3(2):121. 3271813
49. Heras P, Kritikos K, Hatzopoulos A, Georgopoulou AP. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European Journal of Cancer Care 2009;18(6):653-6. 3271814
50. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. Journal of Clinical Endocrinology and Metabolism 2010;95(2):559-66. 3271816
51. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. Journal of Clinical Oncology 2008;26(29):4739-45. 3271817
52. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double-blind placebo-controlled multicenter study. Anticancer Research 1999;19(4C):3383-92. 3271819
53. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19(6):663-7. 3271821
54. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. Journal of Clinical Oncology 2005;23(15):3314-21. 3271823
55. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomised study. Journal of Internal Medicine 1999;246(1):67-74. 3271825
56. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica 2008;47(4):740-6. 3271827
57. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clinical Cancer Research 2008;14(20):6690-6. 3271829
58. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. Journal of Clinical Oncology 2007;25(28):4431-7. 3271830
59. Mardiak J, Bohunicky L, Chovanec J, Salek T, Koza I. Adjuvant clodronate therapy in patients with locally advanced breast cancer - long term results of a double blind randomised trial. Neoplasma 2000;47(3):177-80. 3271835
60. Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 1991;48(2):97-101. 3271837
61. Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, et al. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - the phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). European Journal of Cancer 2016;64:12-21. 6946395
62. NCT00512993 . Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN). clinicaltrials.gov/ct2/show/NCT00512993 Date first received: 3 August 2007. 6946396
63. von Minckwitz G, Rezai M, Eidtmann H, Tesch H, Huober J, Gerber B, et al. Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer - the phase III NATAN study (GBG 36/ABCSG XX). Cancer Research 2013;73(24 Suppl):S5-05. 6946397
64. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncology 2012; Vol. 13, issue 7:734-42. 6946399
65. Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. NSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - final analysis. Cancer Research 2011;71(24 Suppl):S2-3. 6946400
66. Hortobagyi GN, Lipton A, Chew HK, Gradishar WJ, Sauter NP, Mohanlal RW, et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. Journal of Clinical Oncology 2014;32(5 Suppl):LBA9500. 6946402
67. NCT00320710 . Efficacy and safety of zoledronic acid (every 4 weeks vs every 12 weeks) in patients with documented bone metastases from bone cancer. clinicaltrials.gov/ct2/show/NCT00320710 Date first received: 28 April 2006. 6946403
68. Paterson AHG, Kanis JA, Powles TJ, McCloskey EV, Archabault WT, Kurman MR, et al. A re-analysis of a trial of clodronate in patients with breast cancer and bone metastases. Anthra Pharmaceuticals. 3271839
69. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993;11(1):59-65. 3271840
70. Atula ST, Paterson AHG, Powles TJ, McLoskey EV, Nevalainen JI, Kanis JA. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Safety 2003;26(9):661-71. 6946405
71. McCloskey E, Paterson A, Kanis J, Tahtela R, Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer 2009;46(3):558-65. 6946406
72. Powles T, McCloskey E, Kurkilahti M, Kurkilahti M, Kanis J. Oral clodronate for the adjuvant treatment of operable breast cancer: results of a randomised, double-blind, placebo-controlled multicenter trial. Journal of Clinical Oncology 2004;22(14 Suppl):528. 6946407
73. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Research 2006;8(2):13. 6946408
74. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. Journal of Clinical Oncology 2002;20(15):3219-24. 6946409
75. Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98(8):1735-44. 3271851
76. Rosen LS, Gordon D, Dugan W, Major P, Eisenberg PD, Provencher L, et al. Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100(1):36-43. 3271852
77. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer 2001;7(5):377-87. 3271853
78. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology 2001;19(1):10-17. 6946411
79. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncologica 2004;43(7):650-6. 6946412
80. Body JJ, Von Moos R, Stopeck A, Qian Y, Braun A, Chung K. Health resource utilization of subjects receiving denosumab and zoledronic acid in a randomized phase 3 trial of advanced breast cancer patients with bone metastases. Value in Health 2010;13:A279. 3271858
81. Cleeland CS, Body JJ, Stopeck A, Von Moos R, Fallowfield L, Mathias SD, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013;119(4):832-8. 3271859
82. De Boer R, Steger G, Von Moos R, Martin M, Stopeck A, Tonkin K, et al. A number needed to treat (NNT) analysis of the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMS). Journal of Oncology Pharmacy Practice 2012;18:22. 3271862
83. De Boer RH, Stopeck A, Fallowfield L, Patrick D, Cleeland CS, Steger GG, et al. Pain in patients with metastatic breast cancer: results from a phase III trial of denosumab versus zoledronic acid. Asia-Pacific Journal of Clinical Oncology 2012;8:40. 3271861
84. De Boer RH, Stopeck AT, Lipton A, Martin M, Body JJ, Paterson A, et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: a pre-specified two year open-label extension treatment phase of a pivotal phase iii study. Asia-Pacific Journal of Clinical Oncology 2012;8:44. 3271860
85. Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, et al. Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer 2011;47:S237. 3271863
86. Fallowfield L, Cleeland CS, Body JJ, Stopeck A, Von Moos R, Patrick DL, et al. Pain severity and analgesic use associated with skeletal-related events in patients with advanced breast cancer and bone metastases. Cancer Research 2011;71(24 Suppl):P4-13-01. 3271864
87. Fallowfield L, Patrick D, Body J J, Lipton A, Tonkin K S, Qian Y, et al. Health-related quality of life in patients with metastatic breast cancer treated with denosumab or zoledronic acid. Supportive Care in Cancer 2012;20:S37. 3271866
88. Fallowfield L, Patrick D, Body J, Lipton A, Tonkin K S, Qian Y, et al. Effect of denosumab versus zoledronic acid on health-related quality of life in patients with metastatic breast cancer. Journal of Clinical Oncology 2011;29(27 Suppl):272. 3271867
89. Fallowfield L, Patrick D, Body JJ, Lipton A, Tonkin KS, Qian Y, et al. Abstract P1-13-05: The effect of treatment with denosumab or zoledronic acid on health-related quality of life in patients with metastatic breast cancer 262 2631. Cancer Research 2010;70:1-13. 3271865
90. Lipton A, Fizazi K, Stopeck A, Henry DH, Smith MR, Shore ND, et al. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: subgroup analyses by baseline characteristics. Journal of Clinical Oncology 2014;32(15 Suppl):9501. 3271868
91. Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clinical Cancer Research 2012;18:4841-9. 3271869
92. Spencer A, Diel I, Body J J, Stopeck A, Vadhan-Raj S, Steger G, et al. Effect of denosumab treatment on prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Journal of Oncology Pharmacy Practice 2012;18:22-3. 3271871
93. Spencer A, Diel IJ, Body JJ, Stopeck A, Vadhan-Raj S, Steger GG, et al. Prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease: a post-hoc analysis of the effect of denosumab treatment. Asia-Pacific Journal of Clinical Oncology 2012;8:45-6. 3271870
94. Stopeck A, De Boer R, Fujiwara Y, Lichinitser M, Tonkin K, Yardley D, et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. Cancer Research 2009;69(24 Suppl):09-22. 3271876
95. Stopeck A, Fallowfield L, Patrick D, Cleeland CS, De Boer RH, Steger GG, et al. Effects of denosumab versus zoledronic acid (ZA) on pain in patients with metastatic breast cancer: results from a phase III clinical trial. Journal of Clinical Oncology 2010;28(15 Suppl):1024. 3271877
96. Stopeck A, Martin M, Ritchie D, Body JJ, Paterson A, Viniegra M, et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Cancer Research 2010;70(24 Suppl):P6-14-01. 3271878
97. Stopeck AT, Lipton A, Martin M, Body JJ, Paterson A, Steger GG, et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3 study. Cancer Research 2011;71(24 Suppl):P3-16-07. 3271874
98. Stopeck AT, Lipton A, Martin M, Body JJ, Paterson A, Steger GG, et al. Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab. European Journal of Cancer 2012;48(4 Suppl):S3. 3271875
99. Stopeck AT, Lipton AA, Campbell-Baird C, von Moos R, Fan M, Haddock B, et al. Abstract P6-14-09: Acute-phase reactions following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 study in patients with breast cancer and bone metastases. Cancer Research 2010;70(24 Suppl):P6-14-09. 3271872
100. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, De Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. Journal of Clinical Oncology 2010;28(35):5132-9. 3271879
101. Gralow J, Barlow WE, Paterson AHG, Lew D, Stopeck A, Hayes DF, et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology 2015;33(15 Suppl):503. [0732-183X]6946414
102. Gralow J, Barlow WE, Paterson AHG, Lew D, Stopeck A, Hayes DF, et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient-stated preference for oral versus intravenous delivery. Journal of Clinical Oncoloy 2014;32(15 Suppl):558. 6946415
103. NCT00127205 . Zoledronate, clodronate, or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. clinicaltrials.gov/ct2/show/NCT00127205 (accessed 30 April 2011); Vol. Date first received: 3 August 2005. 6946416
104. Leal T, Tevaarwerk A, Love R, Stewart J, Binkley N, Eickhoff J, et al. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Clinical Breast Cancer 2010;10(6):471-6. 3271881
105. Tevaarwerk A, Stewart JA, Love R, Binkley NC, Black S, Eickhoff S, et al. Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer. Journal of Clinical Oncology 2007;25(18 Suppl):19558. 3271882
106. Tripathy D, Lichinitzer M, Lazarev A, MacLachian A, Apffelstaedt J, Budde M, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomised, double-blind, placebo-controlled trial. Annals of Oncology 2004;15(5):743-50. 3271884
107. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bulletin du Cancer 2001;88(7):701-7. 3271886
108. Cleton FJ, Van Holten-Verzantvoort AT, Bijvoet OLM. Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer patients. Recent Results in Cancer Research. Vol. 116, Berlin-Heidelberg: Springer-Verlag, 1989:73-8. 3271888
109. Van Holten-Vaerzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993;11(3):491-8. 3271889
110. Van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harinck HIJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987;330(8566):983-5. 3271890
111. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, Hermans J, Van Emmerik B, Van Dam FSAM, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer 1991;27(5):544-9. 3271891
112. Van Holten-Verzantvoort AT, Hermans J, Beex LVAM, Blijham G, Cleton FJ, Van Eck-Smit BCF, et al. Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?. European Journal of Cancer 1996;32A(3):450-4. 3271893
113. von Au A, Milloth E, Diel I, Stefanovic S, Hennigs A, Wallwiener M, et al. Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority phase III trial. OncoTargets and Therapy 2016; Vol. 2016, issue 9:4173-80. 6946418
114. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13(5):503-14. 6946420
115. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology 2007;25(7):829-36. 6946421
116. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012;118(5):1192-201. 6946422
117. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clinical Breast Cancer 2009;9(2):77-85. 6946423
118. Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, et al. Erratum [Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial]. Lancet Oncology 2014;15(2):e52-3. 6946425
119. Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncology 2014;15(1):114-22. 6946426
120. Barrett-Lee PJ, Casbard A, Abraham J, Grieve R, Wheatley D, Simmons P, et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial-first results of a UK NCRI 1, 405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. Cancer Research 2012;72(24 Suppl):PD07-09. 6946427
121. NCT00326820 . Ibandronate or zoledronate in treating patients with newly diagnosed bone metastases from breast cancer. clinicaltrials.gov/ct2/show/NCT00326820 Date first received: 16 May 2006. 6946428
122. Nelson A, Fenlon D, Morris J, Sampson C, Harrop E, Murray N, et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials 2013;14:325. 6946429
123. Coleman R, De Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology 2013;24(2):398-405. 6946431
124. Coleman R, De Boer R, Eidtmann H, Neven P, von Minckwitz G, Martin N, et al. Influence of delayed zoledronic acid initiation on disease-free survival in postmenopausal women with endocrine receptor-positive early breast cancer receiving adjuvant letrozole: exploratory analysis from the ZO-FAST trial. Cancer Research 2011;71(24 Suppl):P2-17-01. 6946432
125. De Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, et al. Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST. Cancer Research 2011;71(24 Suppl):S1-3. 6946433
126. De Boer R, Martin M, Steger GG, Von Moos R, Stopeck A, Tonkin K, et al. Assessing the benefit of denosumab therapy among patients with breast cancer and bone metastases (BMs): a number-needed-to-treat (NNT) analysis. Asia-Pacific Journal of Clinical Oncology 2011;7(3 Suppl):9. 6946434
127. Eidtmann H, De Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of Oncology 2010;21(11):2188-94. 6946435
128. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncology 2013;14(7):663-70. 6946437
129. NCT00375427 . Safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions. clinicaltrials.gov/ct2/show/NCT00375427 Date first received: 12 September 2006. 6946438
130. NCT00525759 . Investigating the biological effects of the addition of zoledronic acid to pre-operative chemotherapy in breast cancer (ANZAC). clinicaltrials.gov/ct2/show/NCT00525759 Date first received: 5 September 2007. 6946440
131. Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study. Clinical Cancer Research 2013;19(10):2755-65. 6946441
132. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zolendronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomised dose-response study. Cancer 2001;91(7):1191-200. 3271905
133. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. Journal of Clinical Oncology 1997;15(3):955-62. 3271907
134. Fuleihan G, Salamoun M, Mourad Y, Chehal A, Salem Z, Mahfoud Z, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomised controlled trial. Journal of Endocrinology and Metabolism 2005;90(6):3209-14. 3271909
135. Greenspan S, Perera S, Vujevich K, Van Londen G, Brufsky A, Lembersky B, et al. Prevention of bone loss in breast cancer survivors on aromatase inhibitors: results of the Rebbeca II trial. Journal of Bone and Mineral Research 2013;28(1 Suppl):1050. 3271911
136. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, et al. Risedronate prevents bone loss in breast cancer survivors: 2-year, randomized, double-blind, placebo-controlled clinical trial. Journal of Clinical Oncology 2008;26(16):2644-52. 3271912
137. Hines S, Mincey B, Sloan J, Thomas S, Chottiner E, Loprinzi C, et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. Journal of Clinical Oncology 2009;27(7):1047-53. 6946443
138. Jagdev SP, Purohity P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Annals of Oncology 2001;12(10):1433-8. 3271914
139. Kokufu I, Kohno N, Yamamoto M, Takao S. Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes. Oncology Letters 2010;1(2):247-52. 3271916
140. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Clondronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Research and Treatment 2005;90:117-25. 3271918
141. Mathevet P, Magaud L, Clezardin P. Adding zoledronic acid to neo-adjuvant chemotherapy may improve the efficiency of chemotherapy in locally advanced breast cancer: results from the prospective randomized study NEOZOL. Cancer Research 2016;76(4 Suppl):P6-13-19. [0008-5472]6946445
142. McCloskey E, Paterson A, Kanis J, Tahtela R, Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer 2009;46(3):558-65. 3271920
143. Hadji P, Kauka A, Ziller M, Birkholz K, Baier M, Muth M, et al. Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study. Breast Cancer Research & Treatment 2014;144:343-51. 6946447
144. Hadji P, Kauka A, Ziller M, Birkholz K, Baier M, Muth M, et al. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Osteoporosis International 2014;25(4):1369-78. 6946448
145. Kalder M, Kyvernitakis I, Albert US, Baier-Ebert M, Hadji P. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Osteoporosis International 2015;26(1):353-60. 6946449
146. Saarto T, Taube T, Blomqvist C, Vehmanen L, Elomaa I. Three-year oral clodronate treatment does not impair mineralization of newly formed bone-a histomorphometric study. Calcified Tissue International 2005;77(2):84-90. 3271926
147. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomised controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncology 2004;43(7):650-6. 3271927
148. Livi L, Meattini I, Scotti V, Saieva C, Desideri I, Carta GA, et al. BONADIUV trial: a single blind, randomized placebo controlled phase II study using oral ibandronate for osteopenic women receiving adjuvant aromatase inhibitors: final safety analysis. Journal of Clinical Oncology 2016;34(15 Suppl):e12043. [1527-7755]6946451
149. Scotti V, Meattini I, Cecchini S, De Feo ML, Saieva C, De Luca Cardillo C, et al. A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral bisphosphonate treatment on bone mineral density in osteopenic women receiving adjuvant aromatase inhibitors: Interim analysis of "BONADIUV" trial. Journal of Clinical Oncology 2014;32:TPS658. 6946452
150. Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncology 2014;15(13):1460-8. [ISRCTN31488319]6946454
151. Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, et al. Correction to Lancet Oncology 2014; 15: 1464. Lancet Oncology 2014;15(13):e587. 6946455
152. Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. American Journal of Medicine 1983;74(3):401-6. 3271933
153. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Breast Cancer Research and Treatment 2001;37:2373-8. 3271935
154. Vehmanen L, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Research and Treatment 2004;87:181-8. 3271937
155. Weinfurt KP, Catel LD, Li Y, Timie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Medical Care 2004;42(2):164-75. 3271939
156. Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP, Hayward L, et al. Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. Journal of Clinical Oncology 2012;30(15 Suppl (May 2012)):511. 6946457
157. NCT00458796 . Comparison of two schedules of zoledronic acid in treating patients with breast cancer that has spread to the bone. clinicaltrials.gov/ct2/show/NCT00458796 Date first received: 9 April 2007. 6946458
158. Addison CL, Zhao H, Mazzarello S, Mallick R, Amir E, Tannock I, et al. Effects of de-escalated bisphosphonate therapy on bone turnover or metastasis markers and their correlation with risk of skeletal related events - a biomarker analysis in conjunction with the REFORM study. Cancer Research 2012;72(24 Suppl):P2-05-12. 3271941
159. Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, et al. Randomized feasibility study of de-escalated (Every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. American Journal of Clinical Oncology 2013;36(5):436-42. 3271942
160. Amir E, Freedman O, Carlsson L, Usmani T, Lee E, Dranitsaris G, et al. Pilot randomized trial of de-escalated (q12 weekly) versus standard (q3-4 weekly) intravenous bisphosphonates in women with low-risk bone metastases from breast cancer. Cancer Research 2011;71(24 Suppl):P4-16-08. 3271943
161. Bell R, Goss PE, Barrios CH, Finkelstein D, Iwata H, Martin M, et al. A randomised, double-blind, placebo-controlled multicentre phase 3 study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-care). Asia-Pacific Journal of Clinical Oncology 2011;7:150. 6946460
162. Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, et al. A phase 3 randomized, double-blind, placebo-controlled multicenter study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). Cancer Research 2011;71(24 Suppl):OT1-01. 6946461
163. Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, et al. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). Journal of Clinical Oncology 2011;29(15 Suppl):published online before print. 6946462
164. Goss PE, Barrios CH, Bell R, Finkelstein DM, Iwata H, Martin M, et al. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): an international, randomized, double-blind, placebo-controlled phase III clinical trial. Journal of Clinical Oncology 2012;30(15 Suppl):Published online before print. 6946463
165. Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, et al. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): a global, placebo-controlled, randomized, double-blind, phase 3 clinical trial. Cancer Research 2013;73:OT2-6. 6946464
166. Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, et al. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): an international, placebo-controlled, randomized, double-blind phase III clinical trial. Journal of Clinical Oncology 2013;31(15 Suppl):published online before print. 6946465
167. Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, et al. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): an international, randomized, double-blind, placebo-controlled phase 3 clinical trial. Cancer Research 2012;72(24 Suppl):OT2-3-03. 6946466
168. NCT01077154 . Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). clinicaltrials.gov/ct2/show/NCT01077154 Date first received: 4 February 2010. 6946467
169. El-Ibrashi MM, El-Sadda WM, bdel-Halim II, Elashri MS. Zoledronic acid combined with adjuvant tamoxifen with or without ovarian function suppression in premenopausal early breast cancer patients. Cancer Research 2016;76(4 Suppl):P5-15-04. [0008-5472]6946469
170. Fallowfield L, Patrick DL, Von Moos R, Cleeland CS, Zhou Y, Balakumaran A, et al. The impact of skeletal-related events on pain interference in patients with advanced breast cancer and bone metastases. Cancer Research 2015;75(9 Suppl):P5-16-03. 3271956
171. Fasching PA, Jud SM, Hauschild M, Kummel S, Schutte M, Warm M, et al. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer 2014;14:66. 6946471
172. NCT00412022 . HOBOE: a phase 3 study of adjuvant triptorelin and tamoxifen, letrozole, or letrozole and zoledronic acid in premenopausal patients with breast cancer. clinicaltrials.gov/ct2/show/NCT00412022 Date first received: 14 December 2006. 6946473
173. Nuzzo F, Gallo C, Lastoria S, Di Maio M, Piccirillo MC, Gravina A, et al. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Annals of Oncology 2012;23:2027-33. 6946474
174. Jacobs CM, Kuchuk I, Smith S, Mazzarello S, Vandermeer L, Bouganim N, et al. A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study). Journal of Clinical Oncology 2014;32(31 Suppl):155. [Clinicaltrials.gov: NCT01907880]3271967
175. Jiang Z, Shao Z, Zhang Q, Yao Y, He J, Liao W, et al. Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors. Journal of Clinical Oncology 2016;34(15 Suppl):10116. [1527-7755]6946476
176. Hasegawa Y, Tanino H, Horiguchi J, Miura D, Ishikawa T, Hayashi M, et al. Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE Study). PLoS ONE 2015;10(12):e0143643. 6946478
177. Miura D, Hasegawa Y, Horiguchi J, Ishikawa T, Hayashi M, Takao S, et al. Disease-free survival and Ki67 analysis of a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer (JONIE-1 study). Cancer Research 2013;73(24 Suppl):PD3-7. 6946479
178. Sangai T, Ishikawa T, Kohno N, Miura D, Sato E, Kaise H, et al. Exploring biomarkers of response to zoledronic acid in breast cancer from clinical trial result of neoadjuvant chemotherapy with zoledronic acid: JONIE-1 study. Cancer Research 2015;75(9 Suppl):P6-01-02. [0008-5472]6946480
179. Sangai T, Sato E, Ishikawa T, Kaise H, Hasegawa Y, Miura D, et al. Exploring immunomodulatory effects of zoledronic acid in breast cancer from clinical trial result of neoadjuvant chemotherapy with zoledronic acid: JONIE-1 study. Cancer Research 2016; Vol. 76, issue 4 Suppl:P4-09-25. [0008-5472]6946481
180. Kummel S, Von MG, Nekljudova V, Dan CS, Denkert C, Hanusch C, et al. Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules-2x2 factorial design (GeparX). Journal of Clinical Oncology 2016;34(15 Suppl):TPS635. [1527-7755]6946483
181. NCT00196859 . Study in elderly patients with early breast cancer (ICE). clinicaltrials.gov/ct2/show/NCT00196859 Date first received: 12 September 2005. 6946485
182. NCT00301886 . Zoledronate or ibandronate in preventing bone problems in women with stage IV breast cancer that has spread to the bone. clinicaltrials.gov/ct2/show/NCT00301886 (accessed 30 April 2011). 6946487
183. NCT00524849 . Zometa and circulating vascular endothelial growth factor (VEGF) in breast cancer patients with bone metastasis. clinicaltrials.gov/ct2/show/NCT00524849 (accessed 30 April 2011). 3271974
184. NCT01129336 . Effect of zoledronic acid as anti-cancer treatment in metastatic breast cancer patients (Z-ACT 1). clinicaltrials.gov/ct2/show/NCT01129336 (accessed 30 April 2011). 6946489
185. Charehbili A, Hamdy NAT, Smit VTHB, Kessels L, Van Bochove A, Van Laarhoven HW, et al. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). Breast 2016;25:69-74. [0960-9776]6946490
186. Charehbili A, Hamdy NAT, Smit VTHB, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, et al. Changes in circulating vitamin D levels as a predictor for pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC): a Dutch breast cancer trialists group (BOOG) side-study. Cancer Research 2013;73(24 Suppl):P1-08-19. 3271976
187. Charehbili A, Van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Annals of Oncology 2014;25(5):998-1004. 6946491
188. Dekker TJA, Charehbili A, Smit VTHB, Ten DP, Meershoek-Klein KE, Van de Ven S, et al. Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: results from the NEOZOTAC trial. Molecular Oncology 2015;9(6):1120-8. [1574-7891]6946492
189. Dekker TJA, Charehbili A, Smit VTHB, Wasser MNJM, Heijns JB, Van Warmerdam LJ, et al. The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): a Dutch breast cancer trialists group (BOOG) side-study. Cancer Research 2013;73(24 Suppl):P1-06-04. 3271978
190. Van de Ven S, Liefers G, Putter H, Van Warmerdam LJ, Kessels LW, Dercksen W, et al. NEO-ZOTAC: toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC). Cancer Research 2012;72(24 Suppl):PD07-06. 3271979
191. Van de Ven S, Nortier JWR, Liefers GJ, Ten Tije A, Kessels LW, Van Laarhoven HWM, et al. NEO-ZOTAC: a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or locally advanced breast cancer. Cancer Research 2011;71(24 Suppl):OT1-01-04. 3271980
192. NCT02051218 . Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks. clinicaltrials.gov/ct2/show/NCT02051218 Date first received: 29 January 2014. 6946494
193. Templeton AJ, Stalder L, Bernhard J, Brauchli P, Gillessen S, Hayoz S, et al. Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SAKK 96/12, REDUSE). Journal of Clinical Oncology 2014;32(15 Suppl):published online before print. 6946495
194. Andergassen U, Kasprowicz NS, Hepp P, Schindlbeck C, Harbeck N, Kiechle M, et al. Participation in the SUCCESS-A trial improves intensity and quality of care for patients with primary breast cancer. Tumor Diagnostik und Therapie 2013;34:140-6. 6946497
195. Bauer ECA, Neugebauer JK, Andergassen U, Jaeger B, Jueckstock JK, Fasching PA, et al. Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study. Journal of Clinical Oncology 2013;31(15 Suppl):11042. 6946498
196. Janni W, Rack B, Fasching P, Haeberle L, Friedl T, Tesch H, et al. Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis-results from the adjuvant SUCCESS A trial. Cancer Research 2016;76(4 Suppl):S2-03. [0008-5472]6946499
197. NCT02181101 . Simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance-trial SUCCESS-Trial. clinicaltrials.gov/ct2/show/NCT02181101 Date first received: 4 June 2014. 6946500
198. Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, et al. A phase II multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Research and Treatment 2014;144(3):615-624. 6946502
199. Bouganim N, Hilton J, Vandermeer L, Hopkins S, Spencer P, Robbins D, et al. A multicentre study assessing 12-weekly intravenous bisphosphonate therapy in women with low risk bone metastases from breast cancer - the TRIUMPH trial. Cancer Research 2011;71(24 Suppl):OT1-01-02. 6946503
200. Bouganim N, Vandermeer L, Kuchuk I, Dent S, Hopkins S, Song X, et al. Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: a pragmatic multicentre trial. Cancer Research 2012;72(24 Suppl):P3-13-05. 6946504
201. Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, et al. A phase II multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Research and Treatment 2014;144(3):615-624.
202. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncology 2010;11(5):421-8. 3271746
203. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Annals of Statistics 1982;10(4):1100-20.
204. Poznak CHV, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. Journal of Clinical Oncology 2011; Vol. 29, issue 9:1221-7.
205. Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 2017;35(18):2062-81.
206. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. Journal of Clinical Oncology 1998;16(3):1218-25.
207. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, et al. Current use of bisphosphonates in oncology. Journal of Clinical Oncology 1998;16(12):3890-9.
208. Body JJ, Lichinitser MR, Diehl I, Schlosser K, Pfarr E, Cavalli F, et al. Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Annual Meeting of the American Society of Clinical Oncology (ASCO); 1999; Chicago. Chicago: American Society of Clinical Oncology, 1999; Vol. 18:575a. 3271763
209. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treatment Reviews 1985;12:251-70.
210. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. British Journal of Cancer 1987;55(1):61-6.
211. Coleman R, Bundred N, De Boer R, Llombart A, Campbell I, Neven P, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. 32nd Annual San Antonio Breast Cancer Symposium; 2009 Dec 9-13; San Antonio. San Antonio: San Antonio Breast Cancer Symposium (SABCS), 2009.
212. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. British Journal of Cancer 2010;102(7):1099-105. 3271777
213. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, et al. Identifying breast cancer patients at high risk for bone metastases. Journal of Clinical Oncology 2000;18(23):3925-35.
214. Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. Journal of the National Cancer Institute 2001;93(7):534-8.
215. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
216. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Annals of Oncology 2008;19(12):2007-201. 3271796
217. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 3;386(10001):1353-61.
218. Elomaa I, Blomqvist C, Porkka, Holtstrom T, Taube T, Lamberg-Allardt C, et al. Clodronate for osteolytic metastases due to breast cancer. Biomedicine and Pharmacotherapy 1988;42(2):111-6. 3271802
219. Elomma I, Blomqvist L, Porkka L, Lamberg-Allardt C, Borgstrom GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987;8(Suppl 1):53-6. 3271803
220. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology 2014; Vol. 25, issue suppl 3:iii124-37.
221. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015;136:E259-86.
222. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22.
223. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 19 September 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
224. Harvey HA. Issue concerning the role of chemotherapy and hormonal therapy of bone metastases from breast cancer. Cancer 1997;80(8):1646-56.
225. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
226. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
227. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clinical Cancer Research 2004;10(13):4559-67.
228. Hortobagyi GN, Lipton A, Chew HK, Gradishar WJ, Sauter NP, Mohanlal RW, et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. Journal of Clinical Oncology 2014;32(5 Suppl):LBA9500. 3271983
229. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone 1995;17(Suppl 2):101-5.
230. Kozlow W, Guise T. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. Journal of Mammary Gland Biology and Neoplasia 2005;10(2):169-80.
231. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. International Journal of Technology Assessment in Health Care 2005;21(1):119-25.
232. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097]
233. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991;12(Suppl 1):1-6.
234. Mundy GR. Mechanisms of bone metastases. Cancer 1987;80(8):1546-56.
235. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
236. Rogers MJ, Watts DJ, Russell RGG. Overview of bisphosphonates. Cancer 1997;80(8):1652-60.
237. Russell RGG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25(1):97-106.
238. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomised controlled study. Journal of Clinical Oncology 2001;19(1):10-17. 3271855
239. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastases treated with combination chemotherapy. Cancer 1986;58:2589-93.
240. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. [DOI: 10.1136/bmj.c332]
241. Schunemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glaziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
242. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
243. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
244. Templeton AJ, Stalder L, Bernhard J, Brauchli P, Gillessen S, Hayoz S, et al. Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SAKK 96/12, REDUSE). Journal of Clinical Oncology 2014;32(15 Suppl):published online before print. 3271986
245. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo-controlled trial. Journal of Clinical Oncology 1999;17(3):846-54. 3271754
246. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
247. Van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harinck HIJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987;330(8566):983-5. 3271890
248. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, Hermans J, Van Emmerik B, Van Dam FSAM, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. European Journal of Cancer 1991;27(5):544-9. 3271891
249. World Health Organization (WHO). World Cancer Report. The International Agency for Research on Cancer 2003.
250. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003474]
251. Pavlakis N, Schmidt RL, Stockler MR. Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003474.pub2]
252. Matthew HF Wong, Martin Stockler, Nick Pavlakis. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD003474.pub3; PUBMED: 22336790]